医学
前列腺癌
肿瘤科
比例危险模型
前列腺
内科学
阶段(地层学)
转移
流行病学
癌症
单变量分析
生存分析
骨转移
多元分析
古生物学
生物
作者
Jiafeng Shou,Qi Zhang,Shuai Wang,Dahong Zhang
出处
期刊:The Prostate
[Wiley]
日期:2018-02-13
卷期号:78 (7): 491-497
被引量:57
摘要
Background The present of metastases is a poor prognostic factor in prostate cancer, but the prognostic impact of different distant metastases pattern is unclear. The aim of this study is to investigate the impact of different distant metastases pattern on the survival of patients with stage IV prostate cancer. Methods Data queried for this study include prostate cancer (2010‐2014) from the Surveillance, Epidemiology, and End Results (SEER) program. Metastatic distribution information was provided for bone, brain, liver and lung. The overall survival was calculated by the Kaplan‐Meier method. Multivariable Cox regression models were used to analyze survival outcome and risk factors. Results A total of 265 900 eligible patients were identified from SEER database. Among these patients, stage of IV prostate cancer accounted for 7.53% (20 034/265 900) at diagnosis. Patients who suffered metastasis to either one of the four organs occupied 61.24% (12 268/20 034) in stage of IV patients. Comparing with other three single metastases, the patients with liver metastasis exhibited worst OS whose mean survival was 17.529 months ( P < 0.001). The mean survival of metastases with bong and lung was 25.238 months, which was the best survival of the six forms with two metastatic sites ( P < 0.001). The results of univariate survival analysis showed that metastatic forms, race, N‐classification and differentiated grade did not have impact on the overall survival of patients with three metastatic sites (all, P > 0.05). Conclusions In analysis of both one and two metastatic sites, patients with liver metastasis seemed to have worse survival outcome. On the other hand, bone metastasis had better outcome than other three visceral metastases. Knowledge of these differences in metastatic patterns may help to better guide pre‐treatment evaluation of prostate cancer and make determination regarding curative‐intent interventions.
科研通智能强力驱动
Strongly Powered by AbleSci AI